Related Experiment Videos
Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening
1Department of Pathology, School of Medicine, University of California, Los Angeles, USA.
Abstract:
We have examined the distal half of the ataxia-telangiectasia (A-T) gene transcript for truncation mutations in 48 A-T affecteds. We found 21 mutations; 4 of the mutations were seen in more than one individual. Genotyping of the individuals sharing mutations, by using nearby microsatellite markers, established that three of the four groups shared common haplotypes, indicating that these were probably founder effects, not public mutations. The one public mutation was found in two American families, one of Ashkenazi Jewish background and the other not. Most truncations deleted the PI3-kinase domain, although some exceptions to this were found in patients with typical A-T phenotypes. All patients not previously known to be consanguineous were found to be compound heterozygotes when mutations could be identified--that is, normal and abnormal protein segments were seen on SDS-PAGE gels. All 48 patients gave RT-PCR products, indicating the presence of relatively stable mRNAs despite their mutations. These results suggest that few public mutations or hot spots can be expected in the A-T gene and that epidemiological studies of A-T carrier status and associated health risks will have to be designed around populations with frequent founder-effect mutations, despite the obvious limitations of this approach.
Insights
Researchers identified 21 mutations in the ataxia-telangiectasia (A-T) gene, primarily founder effects, not widespread public mutations. This finding impacts future A-T carrier studies and risk assessments.
Area of Science:
- Genetics
- Molecular Biology
- Human Disease Genetics
Background:
- Ataxia-telangiectasia (A-T) is a rare, inherited neurodegenerative disorder.
- Genetic mutations in the A-T gene are the primary cause of the disease.
- Understanding mutation patterns is crucial for genetic counseling and epidemiological studies.
Purpose of the Study:
- To identify truncation mutations in the distal half of the ataxia-telangiectasia (A-T) gene transcript.
- To differentiate between founder effects and public mutations in A-T patients.
- To characterize the impact of mutations on A-T protein and mRNA stability.
Main Methods:
- Sequencing of the distal A-T gene transcript in 48 A-T patients.
- Microsatellite marker analysis for haplotype genotyping.
- SDS-PAGE and RT-PCR to assess protein and mRNA levels.
Main Results:
- Twenty-one truncation mutations were identified in 48 A-T patients.
- Three of four recurrent mutations were attributed to founder effects, with one public mutation found in two families.
- Most mutations affected the PI3-kinase domain; mRNA remained relatively stable despite mutations.
Conclusions:
- Few public mutations are expected in the A-T gene; founder effects are more common.
- Epidemiological studies for A-T carrier status should consider population-specific founder mutations.
- The presence of stable mRNA suggests compensatory mechanisms or specific mutation impacts on protein function.